Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 4
2004 5
2005 4
2006 3
2007 7
2008 9
2009 6
2010 11
2011 17
2012 7
2013 12
2014 14
2015 18
2016 14
2017 15
2018 21
2019 19
2020 13
2021 17
2022 5
2023 14
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

204 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean eun sok kim (21 results)?
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF; EXSCEL Study Group. Holman RR, et al. N Engl J Med. 2017 Sep 28;377(13):1228-1239. doi: 10.1056/NEJMoa1612917. Epub 2017 Sep 14. N Engl J Med. 2017. PMID: 28910237 Free PMC article. Clinical Trial.
C-Reactive Protein Signaling Pathways in Tumor Progression.
Kim ES, Kim SY, Moon A. Kim ES, et al. Biomol Ther (Seoul). 2023 Sep 1;31(5):473-483. doi: 10.4062/biomolther.2023.132. Epub 2023 Aug 11. Biomol Ther (Seoul). 2023. PMID: 37562952 Free PMC article. Review.
USP37 Deubiquitinates CDC73 in HPT-JT Syndrome.
Kim SY, Lee JY, Cho YJ, Jo KH, Kim ES, Han JH, Baek KH, Moon SD. Kim SY, et al. Among authors: kim es. Int J Mol Sci. 2022 Jun 7;23(12):6364. doi: 10.3390/ijms23126364. Int J Mol Sci. 2022. PMID: 35742816 Free PMC article.
Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24-week, multicentre, randomized, double-blind, placebo-controlled, phase III trial.
Kwak SH, Han KA, Kim KS, Yu JM, Kim E, Won JC, Kang JG, Chung CH, Oh S, Choi SH, Won KC, Kim SG, Cho SA, Cho BY, Park KS. Kwak SH, et al. Diabetes Obes Metab. 2023 Jul;25(7):1865-1873. doi: 10.1111/dom.15046. Epub 2023 Mar 23. Diabetes Obes Metab. 2023. PMID: 36872067 Clinical Trial.
204 results